Background: Research focusing on the role of APOE in Parkinson's disease (PD) has been largely inconclusive, creating a broad discrepancy in association studies. Objective: To elucidate the role of APOE alleles in PD risk by studying a large sample size and controlling for population substructure. Patients and methods: In total, 3465 case and control samples were genotyped, obtained from the NINDS Neurogenetics repository. Results: No significant differences in ε4 dosages exist between PD cases and controls. The frequency of ε4 carriers differed slightly between cases and controls at 24% (580/2412) and 26% (270/1053), respectively. Likewise, mean dosages of APOE ε2 were not significantly different between cases and controls. APOE ε2 carriers were observed at a frequency of 13.6% (329/2412) among cases and 15% (158/1053) among controls. Logistic regression models evaluating PD as possibly associated with ε4 or ε2 carrier status and allele dosages yielded no significant results. The mean MMSE score among all PD cases was 28.35 (SD = 2.58) and memory loss was reported in only 11.9% (105/879) of cases. Linear regression models comparing MMSE scores as predicted by ε4 or ε2 carrier status and allele dosages were not significant. Conclusions: There is no association between APOE epsilon alleles and Parkinson's disease.
Introduction
Parkinson's disease (PD), with a prevalence of approximately 2% of the adult population over 65 years of age, is second to Alzheimer's Disease (AD) as the most common neurodegenerative disorder (Nussbaum and Ellis, 2003) . The hallmark clinical features are classically characterized as resting tremor, bradykinesia, rigidity and akinesia; it has been suggested that cognitive deficit is a common feature of PD (Aarsland et al., 2003) .
Neuropathologically, PD patients exhibit neuronal cell death in the substantia nigra and accumulate the insoluble protein, α-synuclein, which aggregates to form Lewy Bodies. In an analogous fashion, those afflicted with AD manifest extensive neuronal cell death while accumulating amyloid β plaques predominately within the cortex and hippocampus (Nussbaum and Ellis, 2003) . One of the predominant genetic risk factors for the development of AD, within the apolipoprotein E gene (APOE), has become a significant target for investigation in neurodegenerative diseases.
Functioning in lipid and lipoprotein transport in plasma and neurons, apolipoprotein E is believed to play a role in amyloid clearance and/or metabolism (Bales et al., 2002) . APOE, located on chromosome 19q13.2, can encode three alleles (ε2, ε3, ε4), with ε3 being the most common universally (Strittmatter and Roses, 1996) . In AD, the ε4 allele has been demonstrated to be a key risk factor for acquiring the disease, while possession of the ε2 allele serves as a protective factor towards AD development (Strittmatter and Roses, 1996) .
In contrast, research focusing on the role of APOE and PD association has been largely inconclusive. Previous work has suggested ε4 as a risk factor for the age of onset, decline in cognitive impairment, and/ or development of dementia in PD, ε2 has also been identified as a potential risk factor in PD, however this is at best a weak effect, and inconsistent across studies (Buchanan et al., 2007; Ezquerra et al., 2008; Gallegos-Arreola et al., 2009; Huang et al., 2006; Huang et al., 2004; Kurz et al., 2009; Lopez et al., 2007; Martinez et al., 2005; Pankratz et al., 2006; Ryu and Kwon, 2010; Vefring et al., 2010) .
The discrepancy in association studies may be largely attributed to several factors: sample size limitations, methodological bias, and discordance in sample ethnicities. Thus, by utilizing a large sample size (n= 3465) and controlling for population substructure using previous immunochip replication data, the purpose of this study was to address inconsistencies previously reported. Excluding a suggestive sexstratified association of females between age at onset with mean ε2 dosage and ε2 carrier status, there were no APOE-disease associations revealed in our analyses. 
